Impact of regulatory science on global public health  by Patel, Meghal & Miller, Margaret Ann
Kaohsiung Journal of Medical Sciences (2012) 28, S5eS9Available online at www.sciencedirect.com
journal homepage: http: / /www.kjms-onl ine.comREVIEW ARTICLE
Impact of regulatory science on global public healthMeghal Patel, Margaret Ann Miller*National Center for Toxicology Research, U.S. Food and Drug Administration, USA
Received 31 August 2011; accepted 20 December 2011
Available online 10 July 2012KEYWORDS
Globalization;
Innovation;
Regulatory science* Corresponding author. FDA, 1090
Building 32, Room 2208, Silver Spring,
E-mail address: Margaret.Miller@fd
1607-551X/$36 Copyright ª 2012, Else
http://dx.doi.org/10.1016/j.kjms.201Abstract Regulatory science plays a vital role in protecting and promoting global public
health by providing the scientific basis for ensuring that food and medical products are safe,
properly labeled, and effective. Regulatory science research was first developed for the deter-
mination of product safety in the early part of the 20th Century, and continues to support inno-
vation of the processes needed for regulatory policy decisions. Historically, public health laws
and regulations were enacted following public health tragedies, and often the research tools
and techniques required to execute these laws lagged behind the public health needs.
Throughout history, similar public health problems relating to food and pharmaceutical prod-
ucts have occurred in countries around the world, and have usually led to the development of
equivalent solutions. For example, most countries require a demonstration of pharmaceutical
safety and efficacy prior to marketing these products using approaches that are similar to
those initiated in the United States. The globalization of food and medical products has
created a shift in regulatory compliance such that gaps in food and medical product safety
can generate international problems. Improvements in regulatory research can advance the
regulatory paradigm toward a more preventative, proactive framework. These improvements
will advance at a greater pace with international collaboration by providing additional
resources and new perspectives for approaching and anticipating public health problems.
The following is a review of how past public health disasters have shaped the current regula-
tory landscape, and where innovation can facilitate the shift from reactive policies to proac-
tive policies.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.3 New Hampshire Avenue,
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2.05.003Introduction
Regulatory agencies such as the United States (U.S.) Food
and Drug Administration (FDA) play an important role in
promoting and protecting public health by preventing or
limiting exposure to unsafe products. Unfortunately, lawsed.
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tive, but are usually enacted following a public health
disaster. The ubiquitous nature of intentional and unin-
tentional contamination of food and medical products, the
problems of misbranded products, and the pandemic
nature of disease and adverse events has led to similar
public health problems across borders throughout time.
Public health laws and regulations developed to address
these public health problems are influenced by current
scientific knowledge and are remarkably similar across the
globe. Implementing new public health laws stimulates the
development of new research tools, and these tools inform
regulatory policy decisions and impact public health both
nationally and internationally. The increase of globalization
in trade of food and medical products, together with the
improvement in regulatory science research tools and
techniques, demands a change in how regulatory science
research is applied to protect and promote public health
globally. Understanding how public health disasters have
shaped the development of health laws and regulations is
critical for understanding the current public health policies
in the U.S. and most developed countries; and for devel-
oping a proactive, rather than reactive, global public health
framework.The reactive nature of FDA regulation: a brief
history
The growth of commerce following the U.S. Civil War led to
a dramatic increase in domestic trade, including the
increased marketing of misbranded and adulterated food
and medicines. To combat this problem, Harvey Washington
Wiley, a federal official working for the U.S. Department of
Agriculture, advocated for federal regulation of food and
medicines, including requirements for accurate labeling,
premarket safety testing, and the use of chemical preser-
vatives only when necessary [1,2].
In 1906, U.S. Congress enacted the Pure Food and Drug
Law, which prohibited the shipping of adulterated and
misbranded food and drugs. However, the federal govern-
ment had to prove that a manufacturer deliberately
intended to harm consumers to take legal action against
the manufacturer. The weaknesses of this approach were
highlighted by several public health problems that occurred
during 1920s and 1930s, the most notable being the sulfa-
nilamide tragedy [2].
In 1937, a company prepared a new formulation of the
medicine sulfanilamide using an ethylene glycol-water
mixture with raspberry flavor. The product was tested for
flavor, appearance, and fragrance, but not toxicity [2]. The
law at the time did not require manufacturing companies to
test new medicines for safety, nor did the law prevent the
sale of dangerous or untested medicines. The product was
widely prescribed to treat streptococcal infections, and
soon there were several reports of illness in patients taking
the medicine. FDA inspectors identified the individual
doctors and pharmacies dispensing the product and
removed it from the market. However, finding all of the
dispensed product was extremely difficult, and ultimately
more than 100 people, many of whom were children, died
from taking the product [1,3].This disaster provided impetus for the 1938 Federal
Food, Drug and Cosmetic Act that required drug manufac-
turers to demonstrate product safety to the FDA prior to
marketing. The law also: required medicines to be labeled
with adequate directions for safe use; prohibited false
therapeutic claims; mandated food standards for packaging
and quality; set tolerances for poisonous substances in
food; authorized factory inspections; and regulated
cosmetics and medical devices [1]. Although manufacturers
were required to demonstrate product safety, the scientific
tools needed to meet this requirement were in their
infancy.
The post-World War II era marked an expansion in bio-
logical sciences with the discovery of many new drugs and
the growth of large pharmaceutical companies [1]. At the
same time, the need to assess the safety of medicine and
set tolerances for poisonous substances in foods stimulated
the growth and development in regulatory science tools and
techniques. There were improvements in animal toxicity
testing, data integrity, and statistical analysis. The FDA
developed a standardized set of animal toxicology tests
with standardized study designs and dosing recommenda-
tions. Clinical research also underwent study design
improvements with the development of randomized
controlled clinical trials [1,2].
Beginning in the 1950s, many public health professionals
recommended that drug safety be considered in light of
product effectiveness. However, once again Congress was
not able to garner support for a stronger drug law until
another tragedy occurred, this time with thalidomide [1].
Between 1957 and 1961, thalidomide was widely used in
Europe to treat “morning sickness” in pregnant women.
During this time, more than 10,000 children in 46 countries
were born with limb defects. In 1961, a German pediatri-
cian linked the birth defects to thalidomide exposure
during the first trimester of pregnancy. Thalidomide was
then removed from the European market [4]. The U.S.
escaped the disaster because the FDA concluded that
additional studies were needed to meet the safety stan-
dards outlined in the 1938 legislation, keeping thalidomide
out of the American market [1,4]. Congress amended the
drug law in 1962 to require manufacturers to establish
safety and effectiveness of drugs through adequate, well-
controlled clinical trials prior to domestic marketing [2].
By the end of the 20th century, most industrialized coun-
tries required pre-market safety testing of drugs and food
additives [1].
In the 1990s, many drugs were removed from the market
due to serious adverse events discovered after approval. In
1999, FDA approved Vioxx for the relief of arthritis pain in
adults and children. Vioxx had received a “priority” review
by the FDA because it was a selective COX-2 inhibitor
designed to provide pain relief for inflammatory conditions
while decreasing the risk of gastrointestinal bleeding
caused by nonselective nonsteroidal anti-inflammatory
drugs (NSAIDs) [5]. Because this selectivity was considered
a significant improvement over the existing pain-relieving
drugs, Vioxx was widely prescribed to patients and
quickly became the leading prescription drug used to treat
arthritis [6]. Immediately after its approval, Merck began
a study designed to measure the possible beneficial effects
of Vioxx on the stomach compared to another NSAID
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that the risk of serious cardiovascular events, such as heart
attacks and strokes, increased in patients taking Vioxx
compared to naproxen. Based on these results, in 2001, FDA
requested that Merck include a warning about the adverse
cardiovascular side effects in the label [5,6].
The results of post-market surveillance studies sug-
gested that of the millions of people exposed to Vioxx,
thousands suffered cardiovascular side effects or died. FDA
estimated that Vioxx contributed to approximately 28,000
heart attacks and sudden cardiac deaths between 1999 and
2003. To investigate these postmarket surveillance findings,
Merck conducted an additional study in 2004, which
confirmed the cardiovascular risks associated with Vioxx
use, and led to the voluntary withdrawal of Vioxx that same
year [6].
This public health disaster occurred despite the
premarket safety studies conducted in animals and exten-
sive clinical studies in humans because the cardiovascular
events were too rare to be detected until the product was
used in a very large population [7]. This incident demon-
strates the importance of pharmacovigilance (i.e. the
continued monitoring of an approved product in the general
population) to identify rare and severe adverse events
quickly and avert a significant public health disaster [8].Current regulatory paradigm and international
engagement
Although primarily a domestic agency, FDA has long sup-
ported regulation of the global marketplace through its
early and strong regulatory authority, its innovative
approaches to developing and advancing regulatory science
and its reputation for conducting state-of-the-art regula-
tory research [7,9]. The thalidomide tragedy was an inter-
national disaster that: 1) shaped legislation in the U.S.; 2)
fostered the development of the current regulatory para-
digm for pharmaceuticals; and 3) promoted the adoption of
equivalent regulatory approaches internationally.
Under the modern regulatory paradigm for pharmaceu-
ticals (Fig. 1), product development and design is research-
based and sponsored by industry to meet patient needs and
economic demands. Basic research identifies the mecha-
nism of disease, which can lead to the identification of drugFigure 1. Current medical product regulatory paradigm.targets for interventions and eventually candidate drugs.
These early industry-sponsored studies on the development
of candidate drugs are generally not submitted for regula-
tory review [7].
Once a candidate drug is identified, the drug’s sponsor
conducts preclinical studies, i.e., in vitro and animal safety
testing to demonstrate that the product is reasonably safe
for use in humans [8]. These studies are reviewed by the
FDA to identify an initial safe dose for humans, undesirable
pharmacological activity, safety parameters for clinical
monitoring and the effect on the major physiological
systems prior to clinical development. Once the FDA has
determined that the drug is safe for humans, the drug
begins clinical development. Clinical development includes
Phase I, II, and III clinical trials, pharmacokinetics, phar-
macodynamics, and studies to investigate special toxicities.
During Phase I trials, a drug is tested in healthy volunteers
to determine the acute toxicity, safety in terms of phar-
macokinetics, possible side effects and the maximum safe
dose [7,10]. Phase II trials are conducted in volunteers who
have the disease to determine the safety of the drug, the
correct dosage and the short-term side effects. Phase III
trials confirm efficacy seen in Phase II trials. In this phase,
the drug is typically tested in double-blind, placebo-
controlled trials to demonstrate effectiveness, and estab-
lish the side effects and adverse events associated with
use. Subjects selected for Phase III trials are homogenous to
increase the likelihood that product efficacy will be
demonstrated [7]. Based on all the data submitted to the
FDA for review, a medical product is either accepted or
rejected for approval. If approved, additional postmarket
(or Phase IV) studies may be required to ensure the prod-
uct’s safety in the general population. All approved medical
products are monitored by passive surveillance to deter-
mine adverse events and deviations in product quality
[7,10].
The pharmaceutical regulatory framework, which
evolved in the U.S., influenced regulatory authorities in
other countries that adopted similar laws and regulatory
approval paradigms, including phased studies and good
manufacturing practices [9]. This harmonization through
“the duplication of legislation” across nations illustrates
FDA’s leadership and partnership in the globalized world of
pharmaceuticals [9]. Once similar testing paradigms were
adopted by other regulatory agencies, pharmaceutical
development evolved into a harmonized process through
the efforts of the International Conference on Harmoniza-
tion (ICH). The ICH provides guidance on harmonized
protocols for determining safety and efficacy, product
quality through manufacturing standards and preclinical
safety standards. The ICH also brings together the regula-
tory authorities and pharmaceutical industries of Europe,
Japan and the U.S. to discuss scientific and technical
aspects of drug approval [11].
Although not a regulatory agency, the World Health
Organization (WHO) assures the safety of pharmaceutical
products for the world. The WHO is the international health
authority within the United Nations’ system with a goal of
the “attainment of the highest possible levels of health by
all people” [12]. The WHO publishes an essential drug list
comprised of the drugs required for primary health care for
all people. In 1979, the WHO Action Programme provided
Figure 2. Future medical product regulatory paradigm.
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globe. The WHO also monitors adverse drug reactions
(ADRs), and since the 1960s, has promoted global drug
safety through its International Drug Monitoring Programme
[13]. This WHO program uses pharmacovigilance to: 1)
enhance patient care and safety by preventing unintended
harm from the use of medicines; 2) improve public health
and safety by providing reliable, comprehensive informa-
tion for the prudent use of medicines; and 3) contribute to
the risk-benefit profile of medicines by encouraging safer,
more effective use of medicines [8]. As a result of the
International Drug Monitoring Programme, nearly 100
countries have national databases to report ADRs [13].
Food must also be assessed for safety. Additives, both
direct and indirect, and contaminants, both avoidable and
unavoidable, are regulated by the FDA. Food additives are
subjected to a standard battery of toxicology studies,
including reproductive and genetic toxicity testing, to
establish a no observed effect level (NOEL), taking the
threshold into account. To assess safety for human use,
safety factors are applied to the NOEL established for the
most sensitive, toxic endpoint determined by the most
sensitive animal toxicity test. These safety factors, gener-
ally in powers of 10, are applied to establish a margin of
safety between the dose that causes the effect in animals
and the dose to which humans are to be exposed [14].
Food contaminants are classified as either avoidable or
unavoidable. For avoidable contaminants, such as fish
toxins or microbial contamination, no safe levels are set
since these contaminants should not be in food [15]. For
unavoidable contaminants, such as aflatoxins and poly-
halogenated aromatic hydrocarbons, regulators set
permissible levels that balance the health risks versus the
unavoidable nature of contaminants [15]. Data on
unavoidable contaminants comes from a variety of sources
including animal toxicology studies and epidemiological
studies on accidental exposures. The permissible levels for
unavoidable, carcinogenic contaminants are set by a quan-
titative risk assessment process that usually assumes that
no threshold exists, i.e. the carcinogenic processes are
linear to the low dose [14,16]. Exposure assessments for
food contaminants can be difficult because the relative
contribution of each contaminant can change with
different sources [16].
The WHO, in collaboration with the Food and Agriculture
Organization (FAO) of the United Nations, provides scien-
tific food safety advice, establishes international food
safety standards and helps countries develop food safety
control systems [17]. The Codex Alimentarius Commission,
an intergovernmental body created in 1962, is responsible
for protecting the health of consumers by ensuring fair
practices in food trade, coordinating work on food stan-
dards, implementing the FAO/WHO food safety standards,
and developing guidelines and recommendations to adapt
to emerging food safety issues [18].
Food safety remains a critical national and international
public health priority. With the complexity of the supply
chain through international trade, the safety of food can be
compromised at any point during growth, harvesting,
packaging, and exportation. The regulatory emphasis must
be placed on proper performance of each of the processes,
rather than relying on the inspection of the end product[19]. For example, the development of very rapid microbial
detection methods can identify pathogens in the food
processing environment so they can be eliminated before
the food is contaminated [20].Advancing regulatory science through
innovation and international collaboration
Just as the increase in trade after the Civil War led to the
birth of regulatory science, and the growth of science
during the post-World War II era fostered the development
of regulatory tools and procedures, the end of the Cold War
created a new technological revolution and the globaliza-
tion of markets, including those of food and drugs [2]. To
meet the demand of promoting and protecting public
health in the global context, regulatory science research is
being directed towards delivering the benefits of new and
innovative technologies to consumers while maintaining
product safety and quality [9].
Regulatory science is defined as “the science of devel-
oping new tools, standards and approaches to assess the
safety, efficacy, quality and performance of FDA-regulated
products” [20]. It covers the entire range of scientific
advancements and knowledge needed to ensure food safety
and the safety and efficacy of medical products. The effi-
ciency of the current regulatory paradigm needs improve-
ment to ensure product safety across the complex
international supply chain [19]. The current regulatory
paradigm for medical products is being transformed from
a reactive to proactive framework (Fig. 2) by: 1) integrating
data generated from basic research with clinical outcomes
throughout product development leading to improved risk-
benefit decisions and postmarket surveillance; 2) using
human in vitro testing systems to improve the predict-
ability of animals models; 3) employing innovative clinical
trial designs that change based on the results; and 4)
incorporating genetic and lifestyle information into
preclinical testing and postmarketing surveillance to
reduce adverse events [19,20]. Taking food safety into the
global marketplace demands that regulatory agencies build
partnerships and maximize the multinational collaborations
needed to establish international food recall authority [19].
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is taking a leadership role in conducting research that
fosters and promotes regulatory science. NCTR was estab-
lished in 1971 as a nonregulatory, national resource owned
and managed by the FDA to conduct integrated, toxico-
logical research, and foster interagency, academic, and
industrial collaboration in support of risk assessment needs
related to public health [21]. NCTR is engaged in several
regulatory science research initiatives aimed at improving
the scientific knowledge, tools, standards, and approaches
necessary to assess the safety, efficacy, quality potency,
and performance of medical products and foods including:
1) the development of procedures and protocols to eval-
uate new technologies (e.g. nanotechnology); 2) the eval-
uation of non-invasive, diagnostic technologies for use in
preclinical studies for hazard identification (e.g. bioimag-
ing); 3) improving the efficiency of the regulatory evalua-
tion processes through use of systems approaches (e.g.
biomarker development); and 4) exploring computational
toxicology methods and computer systems for accurate
hazard identification and development of new product
leads (e.g. bioinformatics) [22].
The reality of a global marketplace means that protec-
tion of borders is no longer a viable regulatory framework.
Preventing public health disasters from contaminated or
misbranded food and medicines at the national level
demands an expansion of the national regulatory infra-
structure for all countries in the global economy [20].
Regulatory science requires new collaborations and part-
nerships, the development of new tools and the training of
international scientists to strengthen their national regu-
latory systems [19,20]. Training regulatory scientists in
research is an effective way to advance regulatory science
provided that it is coupled with national resources and
regulatory authority [9,20]. These advancements will
ensure the availability of safe products, and strengthen the
ability to monitor the outcomes of consumer use of prod-
ucts in the global marketplace.References
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